# Kailera funding rounds and investors

As of 14 Oct 2026, Kailera has raised $600M across 1 verified round on record; latest: $600 million Series B led by Bain Capital Private Equity, announced 14 Oct 2025.

Kailera is a late clinical-stage biotechnology company advancing a diversified pipeline of GLP-1 therapies to provide options for people living with obesity

Website: https://kailera.com  
Headquarters: Waltham, Mass.  
Page: https://fireround.dev/companies/kailera.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-10-14 | Series B | $600 million | Bain Capital Private Equity | Adage Capital Management, Atlas Ventures, Bain Capital Life Sciences, Canada Pension Plan Investment Board (CPP Investments), Invus, Janus Henderson Investors, Perseverance Capital, Qatar Investment Authority (QIA), Royalty Pharma, RTW Investments, Sirona Capital, Surveyor Capital (a Citadel company), T. Rowe Price | [investors.kailera.com](https://investors.kailera.com/news-releases/news-release-details/kailera-therapeutics-announces-600-million-series-b-financing), [globenewswire.com](https://www.globenewswire.com/news-release/2025/10/14/3165992/0/en/kailera-therapeutics-announces-600-million-series-b-financing-to-further-advance-pipeline-of-next-generation-therapies-for-the-treatment-of-obesity.html) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.